AZ-WALTON
27.7.2020 15:02:13 CEST | Business Wire | Press release
Walton, a real estate investment and land asset management company with US$3.39 billion under management and administration, has expanded its Builder Option Land Development Funds (BOLD Funds), with an investment objective of raising capital to acquire land identified by large U.S. homebuilders for near-term residential development projects.
The collective $500 million in BOLD Funds -- $250 million U.S. fund targeted at U.S. investors and a separate $250 million offshore fund targeted at non-U.S. resident investors -- provide an alternative investment into real estate assets that support the near-term land inventory needs of leading national homebuilders.
The newly expanded BOLD Funds offer investors, both domestic and internationally, the opportunity to participate in the current growth of the U.S. homebuilding market.
According to a John Burns Housing Survey, new home demand is on fire with June new home sales increasing 55% year-over-year (YOY.) Sales improved in all regions YOY, led by 84% in Florida, 59% in Texas and 54% in the Southeast. Exceeding 2018 and 2019 pricing strength, 57% of builders increased net prices in June, while traffic rating was the best it’s been in four years.
Average finished inventory fell 20% YOY as consumers clamored for quick move-ins and 55% of builders expect good sales in the next six months, compared to 36% one year ago.
The BOLD Funds intend to acquire properties identified by large publicly traded U.S. homebuilders for near-term residential development. The land is then expected to be sold to those same builders in phases with an agreed upon takedown schedule and flexible payment terms. The BOLD Funds expect to make distributions to investors as homes are developed and sold by the builders.
The primary investment objective of the BOLD Funds is to preserve capital investment and generate cash flow through the acquisition and sale of land assets. A purchase and sale agreement with the homebuilder is in place prior to each acquisition which defines the take-down schedule and price per phase. Properties are acquired on an all-cash basis and cash flow is forecast to commence within 6-24 months.
“Walton’s BOLD Funds meet the needs of an evolving homebuilding industry by allowing builders to tie up land inventory with option structures that offer a limited amount of capital down,” said Bill Doherty, CEO, Walton Group of Companies. “Homebuilders are able to improve their ROI by better aligning land inventory costs with cash flow from home sales and investors benefit from a diversified source of cash flow.”
The National Association of Home Builders (NAHB) Housing Market Index (HMI) released in mid-June, reported that builder confidence in the single-family new home market jumped 21 points to 58 in June 2020, also demonstrating that housing stands poised to lead a post-pandemic economic recovery. Any reading above 50 indicates a positive market, stated the Index.
“As the nation re-opens, housing is well-positioned to lead the economy forward,” said NAHB Chairman Dean Mon. “Inventory is tight, mortgage applications are increasing, interest rates are low, and confidence is rising. And buyer traffic more than doubled in one month even as builders report growing online and phone inquiries stemming from the outbreak,” Mon said.
For over 40 years, Walton has researched, planned and structured pre-development land investments located in the major growth corridors throughout the U.S. and Canada. The evolution of Walton has opened the door to offering new products, like its BOLD Funds, creating new opportunities for investors and homebuilders.
About Walton
Walton is a privately owned, leading global real estate investment, land asset management and administration company that has focused on strategically located land in major growth corridors for 40-plus years. The company manages and administers US$3.39 billion of real estate assets in North America, on behalf of its investors and business partners. Walton has more than 104,000 acres of land under ownership, management and administration in the United States and Canada. For more information on Walton, its entities and the company’s portfolio of assets, visit Walton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
